Literature DB >> 6650467

Non-Hodgkin's lymphoma of the stomach.

B Mittal, T H Wasserman, R C Griffith.   

Abstract

Thirty-seven patients with non-Hodgkin's lymphoma of the stomach were treated with curative intent by several single and combined modality regimens. Twenty-two patients presented with stage IE and 15 with stage IIE disease. All but three patients underwent laparotomy. Of all diagnostic procedures used, x-ray of the upper gastrointestinal tract proved to be most helpful in diagnosing malignant lesions (87%). Gastric cytology was suspicious or diagnostic of malignancy in 35% of the patients. Twelve of 34 evaluable patients (35%) developed recurrence. Distant metastases (75%) was the most common mode of failure. The recurrence rates varied by the type of therapy and also the extent of initial disease. Four of 12 patients (33%) were salvaged with retreatment. The 5-year actuarial no evidence of disease survival for the entire group was 61% (stage IE-57%; stage IIE-67%). Patients receiving combined modality therapy had significantly (p = less than 0.05) higher survival than patients treated with single modality treatment. Three of 29 patients (10%) died of surgical complications after gastrectomy. Radiation treatment was well tolerated. Our data and a critical review of the literature do not support the reportedly high incidence of gastric perforation after radiation treatment. We recommend the use of adjuvant radiation for stage IE and adjuvant radiation plus chemotherapy for stage IIE gastric lymphoma.

Entities:  

Mesh:

Year:  1983        PMID: 6650467

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

1.  Long-term follow-up after curative surgery for early gastric lymphoma.

Authors:  D L Bartlett; M S Karpeh; D A Filippa; M F Brennan
Journal:  Ann Surg       Date:  1996-01       Impact factor: 12.969

2.  Malignant gastric lymphoma with spontaneous perforation.

Authors:  Satoko Shimada; Tokichi Gen; Hiroyuki Okamoto
Journal:  BMJ Case Rep       Date:  2013-01-17

3.  [Status of gastrectomy in the multi-modality therapy concept of primary non-Hodgkin's lymphoma of the stomach].

Authors:  P R Verreet; F Borchard; H Stöltzing; K Thon; H D Röher
Journal:  Langenbecks Arch Chir       Date:  1990

Review 4.  Therapy of gastric mucosa associated lymphoid tissue lymphoma.

Authors:  Andrea Morgner; Renate Schmelz; Christian Thiede; Manfred Stolte; Stephan Miehlke
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

Review 5.  The diminishing role of surgery in the treatment of gastric lymphoma.

Authors:  Sam S Yoon; Daniel G Coit; Carol S Portlock; Martin S Karpeh
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

6.  Morphologic analysis of digestive cancers from the registry of Vaud, Switzerland.

Authors:  F Levi; C La Vecchia; S Franceschi; V C Te
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

7.  Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dose-volumetric analysis and its clinical implications.

Authors:  Hyeon Woo Lim; Tae Hyun Kim; Il Ju Choi; Chan Gyoo Kim; Jong Yeul Lee; Soo Jeong Cho; Hyeon Seok Eom; Sung Ho Moon; Dae Yong Kim
Journal:  Radiat Oncol J       Date:  2016-09-28

Review 8.  Perforation caused by gastric mucosa associated lymphoid tissue lymphoma: A case report and literature review.

Authors:  Xinren Ma; Lei Qin; Yueyu Liu; Wuyang Bian; Ding Sun
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

Review 9.  Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma.

Authors:  Daniel Rolf; Gabriele Reinartz; Stephan Rehn; Christopher Kittel; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

10.  Combined surgery and chemotherapy for the treatment of primary gastrointestinal intermediate- or high-grade non-Hodgkin's lymphomas.

Authors:  G Bellesi; R Alterini; A Messori; A Bosi; F Bernardi; S di Lollo; P R Ferrini
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.